// App-Quantinova.ai

108 : A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Fatima H. Karzai

Principal Investigators

  • Michelle A. Ojemuyiwa

  • Anna Couvillon

  • Guinevere Chun

  • Nancy Harold

  • Seth M. Steinberg

  • Douglas K. Price

  • James L. Gulley

  • William Douglas Figg

  • William L. Dahut

  • Ravi Amrit Madan

  • Andrea Borghese Apolo

  • Nancy Ann Dawson

  • Philip M. Arlen

  • Marc Robert Theoret

  • John Joseph Wright

  • Clara Chen

  • Jane B. Trepel

Medical Centers

  • Walter Reed National Military Medical Center, Chevy Chase, MD

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Radiation Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD

  • Biostatistics and Data Management Section, CCR, National Cancer Institute, Bethesda, MD

  • Clinical Center/National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01683994

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved